- Home
- CNFR vs BIAF Comparison
CNFR vs BIAF Comparison
Compare CNFR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- BIAF
- Stock Information
- Founded
- CNFR 2009
- BIAF 2014
- Country
- CNFR United States
- BIAF United States
- Employees
- CNFR N/A
- BIAF N/A
- Industry
- CNFR Property-Casualty Insurers
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNFR Finance
- BIAF Health Care
- Exchange
- CNFR Nasdaq
- BIAF Nasdaq
- Market Cap
- CNFR 13.7M
- BIAF 12.2M
- IPO Year
- CNFR 2015
- BIAF 2022
- Fundamental
- Price
- CNFR $1.00
- BIAF $0.83
- Analyst Decision
- CNFR
- BIAF Strong Buy
- Analyst Count
- CNFR 0
- BIAF 1
- Target Price
- CNFR N/A
- BIAF $6.00
- AVG Volume (30 Days)
- CNFR 4.2K
- BIAF 76.9K
- Earning Date
- CNFR 04-03-2025
- BIAF 03-31-2025
- Dividend Yield
- CNFR N/A
- BIAF N/A
- EPS Growth
- CNFR N/A
- BIAF N/A
- EPS
- CNFR 2.40
- BIAF N/A
- Revenue
- CNFR $74,815,000.00
- BIAF $9,367,785.00
- Revenue This Year
- CNFR N/A
- BIAF $285.51
- Revenue Next Year
- CNFR $7.00
- BIAF $20.05
- P/E Ratio
- CNFR $0.41
- BIAF N/A
- Revenue Growth
- CNFR N/A
- BIAF 2813.87
- 52 Week Low
- CNFR $0.65
- BIAF $0.57
- 52 Week High
- CNFR $1.91
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- CNFR 45.41
- BIAF 52.41
- Support Level
- CNFR $0.96
- BIAF $0.75
- Resistance Level
- CNFR $1.07
- BIAF $0.85
- Average True Range (ATR)
- CNFR 0.04
- BIAF 0.06
- MACD
- CNFR 0.01
- BIAF 0.01
- Stochastic Oscillator
- CNFR 47.78
- BIAF 87.18
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.